SERPINH1 and pulmonary fibrosis: Furthermore, oral administration of surfactin markedly reduced lung hydroxyproline content, demonstrating substantial antifibrotic efficacy <i>in vivo</i>.<h4>Conclusion</h4>Collectively, surfactin are novel inhibitors of the HSP47-collagen interaction with promising therapeutic potential for pulmonary fibrosis treatment.